The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin ...

“Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent ...